{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Y101", "drug-drug interaction", "entecavir", "organic anion transporters", "renal excretion"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36838982", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "28"}, "DateRevised": {"Year": "2023", "Month": "02", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "02", "Day": "20"}], "Language": ["eng"], "ELocationID": ["1995", "10.3390/molecules28041995"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "4", "PubDate": {"Year": "2023", "Month": "Feb", "Day": "20"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro.", "Abstract": {"AbstractText": ["Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular mechanisms of renal excretion and potential drug-drug interactions (DDIs) remain unclear. The present study aimed to determine the organic anion transporters (OATs) involved in the renal disposition of Y101 and to predict the potential DDI between Y101 and entecavir, the first-line agent against HBV and a substrate of OAT1/3. Pharmacokinetic studies and uptake assays using rat kidney slices, as well as hOAT1/3-HEK293 cells, were performed to evaluate potential DDI. The co-administration of probenecid (an inhibitor of OATs) significantly increased the plasma concentrations and area under the plasma concentration-time curves of M8 and M9 but not Y101, while reduced renal clearance and the cumulative urinary excretion of M8 were observed in rats. The time course of Y101 and M8 uptake via rat kidney slices was temperature-dependent. Moreover, the uptake of M8 was inhibited significantly by probenecid and benzylpenicillin, but not by <i>p</i>-aminohippurate or tetraethyl ammonium. M8 was found to be a substrate of hOAT3, but Y101 is not a substrate of either hOAT1 or hOAT3. Additionally, the entecavir inhibited the uptake of M8 in the hOAT3-transfected cells and rat kidney slices in vitro. Interestingly, no significant changes were observed in the pharmacokinetic parameters of Y101, M8 or entecavir, regardless of intravenous or oral co-administration of Y101 and entecavir in rats. In conclusion, M8 is a substrate of OAT3 in rats and humans. Furthermore, M8 also mediates the DDI between Y101 and entecavir in vitro, mediated by OAT3. We speculate that it would be safe to use Y101 with entecavir in clinical practice. Our results provide useful information with which to predict the DDIs between Y101 and other drugs that act as substrates of OAT3."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang 550025, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China."}], "LastName": "Zhang", "ForeName": "Aijie", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China."}], "LastName": "Yang", "ForeName": "Fanlong", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China."}], "LastName": "Yuan", "ForeName": "Yang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China."}], "LastName": "Li", "ForeName": "Cai", "Initials": "C"}, {"Identifier": ["0000-0003-4056-7987"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Dalian Medical University, Dalian 116044, China."}], "LastName": "Huo", "ForeName": "Xiaokui", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Heping District Center for Disease Control and Prevention, Tianjin 300070, China."}], "LastName": "Liu", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}], "LastName": "Zhou", "ForeName": "Shenzhi", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}], "LastName": "Li", "ForeName": "Wei", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}], "LastName": "Zhang", "ForeName": "Na", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China."}], "LastName": "Liu", "ForeName": "Jianfeng", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China."}], "LastName": "Dong", "ForeName": "Shiqi", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, and Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China."}], "LastName": "Fan", "ForeName": "Huirong", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}], "LastName": "Peng", "ForeName": "Ying", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang 550025, China."}], "LastName": "Zheng", "ForeName": "Jiang", "Initials": "J"}], "GrantList": [{"GrantID": "82104284", "Agency": "the National Natural Science Foundation of China", "Country": ""}, {"GrantID": "20JCQNJC00320", "Agency": "the Natural Science Foundation of Tianjin", "Country": ""}, {"GrantID": "2018YFC1708203", "Agency": "the National Key R&D Program of China", "Country": ""}, {"GrantID": "2018PT35031", "Agency": "the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences", "Country": ""}, {"GrantID": "2021-I2M-1-042 and 2022-I2M-2-002", "Agency": "CAMS Innovation Fund for Medical Sciences", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "N-(N-benzoyl-O-(2-dimethylaminoethyl)tyrosyl)phenylalaninol"}, {"RegistryNumber": "5968Y6H45M", "NameOfSubstance": "entecavir"}, {"RegistryNumber": "0", "NameOfSubstance": "Organic Anion Transporters, Sodium-Independent"}, {"RegistryNumber": "0", "NameOfSubstance": "Organic Anion Transport Protein 1"}, {"RegistryNumber": "PO572Z7917", "NameOfSubstance": "Probenecid"}, {"RegistryNumber": "0", "NameOfSubstance": "Dipeptides"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Organic Anion Transporters, Sodium-Independent"}, {"QualifierName": ["metabolism"], "DescriptorName": "Organic Anion Transport Protein 1"}, {"QualifierName": ["metabolism", "pharmacology"], "DescriptorName": "Probenecid"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "HEK293 Cells"}, {"QualifierName": ["metabolism"], "DescriptorName": "Dipeptides"}, {"QualifierName": [], "DescriptorName": "Drug Interactions"}, {"QualifierName": ["metabolism"], "DescriptorName": "Kidney"}], "CoiStatement": "All authors declare that there are no conflict of interest in this study."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Liu X., Xue L., Zhang H., Xu Q., Zhang S., Ma S., Ding X., Liu L., Dong J., Qian L., et al. Phase I, first-in-human, single and multiple ascending dose- and food-effect studies to assess the safety, tolerability and pharmacokinetics of a novel anti-hepatitis B virus drug, bentysrepinine (Y101), in healthy Chinese subjects. Clin. Drug Investig. 2020;40:555\u2013566. doi: 10.1007/s40261-020-00909-3.", "ArticleIdList": ["10.1007/s40261-020-00909-3", "32277364"]}, {"Citation": "Qiu J., Xu B., Huang Z., Pan W., Cao P., Liu C., Hao X., Song B., Liang G. Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. Bioorg. Med. Chem. 2011;19:5352\u20135360. doi: 10.1016/j.bmc.2011.08.001.", "ArticleIdList": ["10.1016/j.bmc.2011.08.001", "21872478"]}, {"Citation": "Xu B., Huang Z., Liu C., Cai Z., Pan W., Cao P., Hao X., Liang G. Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. Bioorg. Med. Chem. 2009;17:3118\u20133125. doi: 10.1016/j.bmc.2009.03.003.", "ArticleIdList": ["10.1016/j.bmc.2009.03.003", "19307124"]}, {"Citation": "Meng F., Xu W., Li Y., Huang Z., Liang G., Liu C. In Silico Molecular Docking Study of Repensine and Bentysrepinine against HBV DNA Polymerase. Chin. Herb. Med. 2015;7:39\u201344. doi: 10.1016/S1674-6384(15)60018-1.", "ArticleIdList": ["10.1016/S1674-6384(15)60018-1"]}, {"Citation": "Yu S., Xu X., Li K., Liang G., Huang Z. Protective effect of phenylalanine dipeptide compounds Y101 on mice models of ANIT hepatic injury. Pharm. J. Chin. PLA. 2011;27:118\u2013121."}, {"Citation": "Yu S., Xu X., Liang G., Huang Z. Protective effects of phenylalanine dipeptide compounds Y101 on liver injury induced by CnoA in mice. Chin. J. New Drugs. 2012;21:78\u201387."}, {"Citation": "Liu X., Huang C., Xue L., Xu Q., Xia W., Li X., Miao L. Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 2018;150:287\u2013293. doi: 10.1016/j.jpba.2017.12.010.", "ArticleIdList": ["10.1016/j.jpba.2017.12.010", "29258048"]}, {"Citation": "Gong M., Meng F., Fan H., Dong S., Wang Y., Li Y., Liang G., Liu C. Molecular Simulation Study on Bentysrepinine Metabolites Improving Binding Affinity of HBV DNA Polymerase. Chin. Herb. Med. 2016;8:139\u2013142. doi: 10.1016/S1674-6384(16)60023-0.", "ArticleIdList": ["10.1016/S1674-6384(16)60023-0"]}, {"Citation": "Ye J., Liu Q., Wang C., Meng Q., Peng J., Sun H., Kaku T., Liu K. Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. Eur. J. Pharm. Sci. 2012;47:341\u2013346. doi: 10.1016/j.ejps.2012.06.004.", "ArticleIdList": ["10.1016/j.ejps.2012.06.004", "22728397"]}, {"Citation": "Huo X., Liu Q., Wang C., Meng Q., Sun H., Peng J., Ma X., Sun P., Liu K. Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats. J. Pharm. Sci. 2014;103:719\u2013729. doi: 10.1002/jps.23805.", "ArticleIdList": ["10.1002/jps.23805", "24338900"]}, {"Citation": "Huo X., Liu K. Renal organic anion transporters in drug-drug interactions and diseases. Eur. J. Pharm. Sci. 2018;112:8\u201319. doi: 10.1016/j.ejps.2017.11.001.", "ArticleIdList": ["10.1016/j.ejps.2017.11.001", "29109021"]}, {"Citation": "Li Y., Meng Q., Yang M., Liu D., Hou X., Tang L., Wang X., Lyu Y., Chen X., Liu K., et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm. Sin. B. 2019;9:1113\u20131144. doi: 10.1016/j.apsb.2019.10.001.", "ArticleIdList": ["10.1016/j.apsb.2019.10.001", "PMC6900561", "31867160"]}, {"Citation": "Tang L.S.Y., Covert E., Wilson E., Kottilil S. Chronic Hepatitis B infection: A review. JAMA. 2018;319:1802\u20131813. doi: 10.1001/jama.2018.3795.", "ArticleIdList": ["10.1001/jama.2018.3795", "29715359"]}, {"Citation": "Yan J.H., Bifano M., Olsen S., Smith R.A., Zhang D., Grasela D.M., LaCreta F. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J. Clin. Pharmacol. 2006;46:1250\u20131258. doi: 10.1177/0091270006293304.", "ArticleIdList": ["10.1177/0091270006293304", "17050790"]}, {"Citation": "Xu Q., Wang C., Meng Q., Liu Q., Sun H., Peng J., Ma X., Kaku T., Liu K. OAT1 and OAT3: Targets of drug-drug interaction between entecavir and JBP485. Eur. J. Pharm. Sci. 2013;48:650\u2013657. doi: 10.1016/j.ejps.2012.12.024.", "ArticleIdList": ["10.1016/j.ejps.2012.12.024", "23313623"]}, {"Citation": "Yang X., Ma Z., Zhou S., Weng Y., Lei H., Zeng S., Li L., Jiang H. Multiple drug transporters are involved in renal secretion of entecavir. Antimicrob. Agents Chemother. 2016;60:6260\u20136270. doi: 10.1128/AAC.00986-16.", "ArticleIdList": ["10.1128/AAC.00986-16", "PMC5038284", "27503646"]}, {"Citation": "Shu W., Ma L., Hu X., Zhang M., Chen W., Ma W., Huang J., Li J. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. Eur. J. Pharm. Sci. 2020;142:105153. doi: 10.1016/j.ejps.2019.105153.", "ArticleIdList": ["10.1016/j.ejps.2019.105153", "31740393"]}, {"Citation": "World Health Organization . Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO; Geneva, Switzerland: 2015.", "ArticleIdList": ["26225396"]}, {"Citation": "Huo X., Meng Q., Wang C., Zhu Y., Liu Z., Ma X., Ma X., Peng J., Sun H., Liu K. Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs) Acta Pharm. Sin. B. 2019;9:986\u2013996. doi: 10.1016/j.apsb.2019.02.005.", "ArticleIdList": ["10.1016/j.apsb.2019.02.005", "PMC6804466", "31649848"]}, {"Citation": "Zhang A., Wang C., Liu Q., Meng Q., Peng J., Sun H., Ma X., Huo X., Liu K. Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans. Drug Metab. Dispos. 2013;41:994\u20131003. doi: 10.1124/dmd.112.049452.", "ArticleIdList": ["10.1124/dmd.112.049452", "23396419"]}, {"Citation": "Mand\u00edkov\u00e1 J., Volkov\u00e1 M., P\u00e1vek P., Navr\u00e1tilov\u00e1 L., Hyr\u0161ov\u00e1 L., Janeba Z., Pavl\u00edk J., B\u00e1rta P., Trejtnar F. Entecavir interacts with influx transporters hOAT1, hCNT2, hCNT3, but not with hOCT2: The potential for renal transporter-mediated cytotoxicity and drug-drug interactions. Front. Pharmacol. 2016;6:304. doi: 10.3389/fphar.2015.00304.", "ArticleIdList": ["10.3389/fphar.2015.00304", "PMC4700268", "26779022"]}, {"Citation": "Matthews S.J. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28:184\u2013203. doi: 10.1016/j.clinthera.2006.02.012.", "ArticleIdList": ["10.1016/j.clinthera.2006.02.012", "16678641"]}, {"Citation": "Zhu Y., Meng Q., Wang C., Liu Q., Sun H., Kaku T., Liu K. Organic anion transporters involved in the excretion of bestatin in the kidney. Peptides. 2012;33:265\u2013271. doi: 10.1016/j.peptides.2012.01.007.", "ArticleIdList": ["10.1016/j.peptides.2012.01.007", "22273603"]}, {"Citation": "Fan H., Zhang A., Liao C., Yang Y., Zhang L., Liu J., Xia Y., Si D., Dong S., Liu C. In vitro metabolism and in vivo pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: Focus on interspecies comparison. Xenobiotica. 2020;50:468\u2013478. doi: 10.1080/00498254.2019.1646946.", "ArticleIdList": ["10.1080/00498254.2019.1646946", "31329010"]}, {"Citation": "Zhu Y., Huo X., Wang C., Meng Q., Liu Z., Sun H., Tan A., Ma X., Peng J., Liu K. Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin. Asian J. Pharm. Sci. 2020;15:252\u2013263. doi: 10.1016/j.ajps.2018.11.006.", "ArticleIdList": ["10.1016/j.ajps.2018.11.006", "PMC7193450", "32373203"]}, {"Citation": "Zhang A., Yang F., Zhao L., Li C., Dong S., Liu J., Fan H. Effects of verapamil on pharmacokinetics of Y101 in vivo in rats. Chin. Pharmacol. Bull. 2021;37:1122\u20131127."}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "10", "Day": "17"}, {"Year": "2023", "Month": "1", "Day": "13"}, {"Year": "2023", "Month": "1", "Day": "25"}, {"Year": "2023", "Month": "2", "Day": "25", "Hour": "4", "Minute": "2"}, {"Year": "2023", "Month": "2", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "3", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["36838982", "PMC9967645", "10.3390/molecules28041995", "molecules28041995"]}}], "PubmedBookArticle": []}